Search for dissertations about: "Magnus Levin"
Found 5 swedish dissertations containing the words Magnus Levin.
-
1. Agreement with Collective Nouns in English
Abstract : This thesis concerns agreement with collective nouns in American, British and Australian English. It is based on material from newspaper corpora and spoken corpora. The findings suggest that dialectal, stylistic, diachronic, syntactic and semantic factors interact in the selection of singular and plural agreement. READ MORE
-
2. Fatigue of Metal Matrix Composites
Abstract : This thesis treats the mechanical properties of discontinuously reinforced metal matrix composites, DMMCs, in general and their fatigue properties in particular. Methods of manufacture, microstructures and resulting mechanical properties of DMMCs are reviewed in the introductory part. READ MORE
-
3. Clustering in Swedish : The Impact of some Properties of the Swedish Language on Document Clustering and an Evaluation Method
Abstract : Text clustering divides a set of texts into groups, so that texts within each group are similar in content. It may be used to uncover the structure and content of unknown text sets as well as to give new perspectives on known ones. READ MORE
-
4. The matter of economic evaluations in health policy decision-making : The case of the Swedish national guidelines for heart diseases
Abstract : Economic evaluations are used to inform decision makers about the efficient allocation of scarce healthcare resources and are generated with the direct intent to support decisions in healthcare. Producing guidelines is a complex process and the inclusion of health-economic aspects in the formulation of the Swedish national guidelines as a basis for the written recommendations (priority gradings), distinguishes them from their European counterparts. READ MORE
-
5. The value of evaluating and implementing pharmaceuticals
Abstract : Pharmaceuticals are a central part of high-quality health care and a resource for improving population health. However, high prices set by private companies who develop and own the rights to new pharmaceuticals question the value that they contribute to the health care system. READ MORE